MYC and B-cell non-Hodgkin lymphoma: Another study of variant MYC translocations in aggressive B-cell lymphomas found patients with 5’MYC gain were more refractory to chemotherapy or had an early relapse with a median event-free survival of only 6 months compared to patients with 3’MYC deletion who often responded to chemotherapy and had an event-free survival of 24 months (34).